The whole blood system can be used to assess candidate drug mode-of-action.
We use the whole blood system to test the mode-of-action of Immuneed’s therapeutic prostate cancer vaccine. The vaccine incorporates long peptides harboring several T cell epitopes. These long peptides are efficiently delivered to specific immune cells by Immuneed’s TET (tetanus-epitope targeting) system that uses MTTE sequences for delivery of the peptides in an antigen-antibody immune complex formula. Since the whole blood loop system has retained intact complement activity, it allows interaction studies of antigen-antibody complexes with human whole blood and complement cascade system. Read more about TET technology under Immuno-Oncology section.
As a test for recall responses, Immuneed also makes use of the immunodominant CMV epitope NLVPMVATV (NLV), incorporated into a synthetic long peptide (SLP). By sampling blood from CMV+/HLA-A*0201 donors, recall responses to the NLV epitope can be studied using flow cytometry and staining for CD8+, tetramer+ cells along with intracellular IFNγ/TNFα production (Figure 7). It is also possible to assess candidate drug mode-of-action to evaluate whether the recall responses can be improved by addition of your candidate drug. Read more about our study in Fletcher J Immunol. 2018 May 11 and about other MOA studies under: Project Examples.